The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...

Promising trial results may be a breakthrough in treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. In patients with muscle-invasive bladder cancer (MIBC) not eligible ...

Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...

Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug combination than with previous therapy options. Institute for Quality and Efficiency in Health Care ...

Pembrolizumab and enfortumab vedotin combination is approved for muscle-invasive bladder cancer in cisplatin-ineligible patients, offering a new treatment option with improved outcomes. The ...

No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. We conducted a phase 3, ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...